Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

14.70USD
4:00pm EDT
Change (% chg)

$-0.10 (-0.68%)
Prev Close
$14.80
Open
$14.85
Day's High
$14.98
Day's Low
$14.40
Volume
355,858
Avg. Vol
201,283
52-wk High
$19.90
52-wk Low
$9.68

MNTA.OQ

Chart for MNTA.OQ

About

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $1,098.13
Shares Outstanding(Mil.): 74.20
Dividend: --
Yield (%): --

Financials

  MNTA.OQ Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -0.41 -- --
ROI: -7.16 2.29 -5.84
ROE: -7.97 0.06 -5.23

BRIEF-Momenta Pharmaceuticals Q1 loss per share $0.46

* Momenta pharmaceuticals reports first quarter 2017 financial results

May 02 2017

BRIEF-Momenta Pharmaceuticals says effective May 1, 2017, Matthew Ottmer will no longer serve as COO of Co

* Momenta pharmaceuticals inc says effective may 1, 2017, matthew ottmer will no longer serve as chief operating officer of co Source text (http://bit.ly/2qpub66) Further company coverage:

May 01 2017

BRIEF-Momenta Pharmaceuticals says U.S. Court of Appeals reversed district court's dismissal filed by Amphastar Pharma against Co

* Momenta Pharmaceuticals- on March 6, U.S. Court of Appeals for first circuit reversed district court's dismissal filed by Amphastar Pharma against Co

Mar 08 2017

UPDATE 1-FDA warns Pfizer over contaminated drugs at Kansas plant

Feb 28 The U.S. Food and Drug Administration said Pfizer Inc's process for manufacturing sterile injectable drugs at a plant in McPherson, Kansas, was "out of control" and put patients at risk, according to a warning letter made public on Tuesday.

Feb 28 2017

BRIEF-Momenta Pharmaceuticals Q4 earnings per share $0.60

* Momenta Pharmaceuticals reports fourth quarter and year end 2016 financial results

Feb 21 2017

BRIEF-Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa

* Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer

Feb 17 2017

BRIEF-Momenta Pharmaceuticals announces HSR clearance

* Momenta Pharmaceuticals announces Hart-Scott-Rodino clearance for collaboration and license agreement with CSL

Feb 17 2017

BRIEF-Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation

* Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation Source text for Eikon: Further company coverage:

Jan 31 2017

BRIEF-Momenta provides year-end 2016 corporate update

* Momenta Pharmaceuticals Inc - reiterated its non-gaap operating expense guidance of approximately $40 - $45 million for Q4 of 2016

Jan 06 2017

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

More From Around the Web

Competitors

Earnings vs. Estimates